Are you sure you want to leave?
17 October 2020
According to new data published by Dr Nahid Tabibzadeh* and colleagues, levels of parathyroid hormone (PTH) prior to initiation of dialysis predict PTH levels and therapeutic strategies during the first year of dialysis.1 A summary of the findings and a link to the full journal article are provided below.
Optimal control of secondary hyperparathyroidism (SHPT) during non-dialysis chronic kidney disease (ND-CKD) may reduce the risk of parathyroid gland hyperplasia and associated resistance to SHPT therapy during dialysis.1–4 However, the evidence for optimal PTH targets and therapeutic strategies in ND-CKD patients is weak.1
The goal of this study by Dr Nahid Tabibzadeh and colleagues, first published online in the journal Nephrology Dialysis Transplantation in October, 2020, was to investigate the relationships between PTH levels prior to initiating dialysis and patient characteristics, treatment patterns and PTH control during the first year of dialysis.1
Dr Tabibzadeh and colleagues evaluated data from phases 4 to 6 (2009 to 2018) of the Dialysis Outcomes and Practice Patterns Study (DOPPS), a multiphase prospective cohort study of patients ≥18 years old who were treated with in-centre haemodialysis in 21 countries.1 They began by stratifying 5,683 incident dialysis patients into seven groups by PTH level, measured immediately prior to initiation of dialysis.1 The groups were less than 50 (5%), 50 to 100 (9%), 100 to 150 (9%), 150 to 300 (30%), 300 to 450 (19%), 450 to 600 (11%) and greater than 600 (16%) pg/mL.†1 The researchers then explored the monthly prevalence of active vitamin D (AVD) and calcimimetics prescriptions over the first year of dialysis, along with the risk of having a PTH level greater than 600 pg/mL after 9 to 12 months of dialysis.1
Compared with the 30% of patients who were initiated on dialysis with a PTH between 150 and 300 pg/mL, the 16% who were initiated on dialysis with a PTH greater than 600 pg/mL:1
The risk of having a PTH greater than 600 pg/mL 9 to 12 months after initiation of dialysis was 29% for patients who were initiated on dialysis with a PTH greater than 600 pg/mL and only 7% for patients who were initiated on dialysis with a PTH between 150 and 300 pg/mL.1 The adjusted risk difference between the two patient groups was 19%, demonstrating a robust association.1
A summary of the study is provided in the shareable infographic below.
Based on these results, Dr Tabibzadeh and colleagues concluded that:1
You can read the full article published by Dr Tabibzadeh and team right now on the Nephrology Dialysis Transplantation website.
Footnotes and references
*Renal Physiology Department, APHP Hôpital Bichat, Université de Paris; Paris, France.
†To convert pg/mL to pmol/L, multiply by 0.106.5
1. Tabibzadeh N et al. Nephrol Dial Transplant. 2021;36(1):160–9.
2. Rodriguez M et al. Am J Renal Physiol. 2005;288:F253–64.
3. Fukuda N et al. J Clin Invest. 1993;92:1436–43.
4. Gogusev J et al. Kidney Int. 1997;51:328–36.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. Kidney Int. 2009;76(Suppl. 113):S1–S130.
You are viewing a website from Vifor Pharma. This material is only intended for healthcare professionals (“HCPs”) from Europe. If you are not the intended audience, please leave this website. By checking the box, you acknowledge that you are a HCP from Europe. Approval conditions for products may vary from country to country. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.
I am residing in:
Bitte verwenden Sie als Benutzernamen die E-Mail Adresse, welche Sie bei der Registration angegeben hatten. Falls Sie das Passwort vergessen haben, können Sie sich einen Reaktivierungslink zustellen lassen. Alternativ ist für bereits registrierte Health Professionals auch eine Anmeldung mit der HPC-Card von FMH oder pharmaSuisse möglich.